A Phase II Study of Epigenetic Therapy With Hydralazine and Magnesium Valproate to Overcome Chemotherapy Resistance in Refractory Solid Tumors.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Hydralazine; Magnesium valproate
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 06 Mar 2007 New trial record.
- 28 Nov 2006 Biomarkers information updated